Climate Change Data

泰宗生物科技股份有限公司

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Established a Sustainability Committee in March 2024.
  • Implemented a comprehensive ESG policy and risk assessment.
  • Regularly conducts performance evaluations of the board and committees.

Climate Goals & Targets

Long-term Goals:
  • Expand into mainland China and Southeast Asia markets.
Medium-term Goals:
  • Establish the company as an international biopharmaceutical company for liver disease prevention and treatment.
  • Continue development of U101, liver cancer early detection and post-surgical monitoring technology, and PTX-9908.
Short-term Goals:
  • Develop U101 for recurrent urinary tract infection, liver cancer early detection and post-surgical monitoring technology, and PTX-9908 liver cancer treatment drug.
  • Expand sales channels for new products.
  • Seek agency/distribution rights for marketable medical devices or pharmaceuticals.

Environmental Challenges

  • High cost and long time frame of new drug development.
  • Risk of new drug development failure.
  • Pressure on product margins due to healthcare price adjustments.
Mitigation Strategies
  • Maintain stable revenue growth from existing products to fund R&D.
  • Seek strategic partnerships with international pharmaceutical companies.
  • Focus on new drug development with lower capital investment and shorter development timelines.
  • Develop high-margin, self-pay products and products with stable sales volume.
  • Actively seek and obtain agency/distribution rights for marketable medical devices or pharmaceuticals.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: ISO 9001, ISO 13485, ISO 17025

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed